Target intelligence / Profile preview

Tumor embolization (arterial supply)

Molecular classification
Other
01

Overview

Tumor embolization is a minimally invasive interventional radiology procedure in which the arterial blood supply to a tumor is deliberately blocked using embolic materials such as particles, microspheres, coils, or chemical agents. The goal is to induce tumor ischemia and necrosis, often as a palliative measure or to reduce surgical blood loss. Embolization can be combined with localized chemotherapy (transarterial chemoembolization, TACE) or radiotherapy (radioembolization), allowing high local drug concentrations while minimizing systemic exposure. Tumor embolization is used in the management of various malignant and some benign solid tumors, particularly when surgical resection is not feasible or as a bridge to surgery or transplantation. This technique is not a molecular target, receptor, enzyme, or transporter, but a therapeutic process[1][2][3][4][5][6][7][8].

Other names
arterial tumor embolizationtransarterial embolizationtransarterial chemoembolizationTAETACEradioembolization
02

Mechanism of action

Physical/chemical blockade of arterial blood flow to tumor tissue, causing ischemia and necrosis[1][2][4][5][6][7]. Local delivery of chemotherapeutics (in TACE) or radiotherapeutics (in radioembolization) directly to the tumor via its arterial supply[3][5][6].

03

Biological functions

Induction of tumor ischemiaReduction of tumor vascularizationFacilitation of tumor necrosis
04

Disease associations

Cancer (especially unresectable solid tumors such as hepatocellular carcinoma, renal cell carcinoma, and some metastatic tumors)
05

Safety considerations

Postembolization syndrome (pain, nausea, vomiting, low-grade fever)Infection or abscess at site of necrotic tumorNon-target embolization (damage to normal tissue)Liver dysfunction or failure (with liver-directed embolization)Vascular injury, bleeding, allergic reactions[5]
06

Interacting drugs

Doxorubicin (as part of transarterial chemoembolization, TACE)

3 more in the full profile.

07

Biomarkers

Imaging markers (reduction in tumor vascularity on angiography, contrast-enhanced CT/MRI)Serum alpha-fetoprotein (for hepatocellular carcinoma response monitoring)

Beyond the preview

Go deeper on Tumor embolization (arterial supply).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor embolization (arterial supply).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call